Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 in Parkinson's disease dementia
2017-004335-36Phase 2Active
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease dementia (PDD) comparing ANAVEX2-73 with Placebo (2 arms). Primary endpoint: Change from baseline to end of treatment in Continuity of Attention. Started Apr 2018; status: active.
02
Drugs
blarcamesine
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on 2017-004335-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004335-36.